UY34666A - Inhibidores de quinasa a base de ariléter - Google Patents

Inhibidores de quinasa a base de ariléter

Info

Publication number
UY34666A
UY34666A UY0001034666A UY34666A UY34666A UY 34666 A UY34666 A UY 34666A UY 0001034666 A UY0001034666 A UY 0001034666A UY 34666 A UY34666 A UY 34666A UY 34666 A UY34666 A UY 34666A
Authority
UY
Uruguay
Prior art keywords
ariléter
kinase inhibitors
based kinase
inhibitors
página
Prior art date
Application number
UY0001034666A
Other languages
English (en)
Inventor
Vivekananda M Vrudhula
Pan Senliang
Rajamani Ramkumar
John E Macor
Joanne J Bronson
Carolyn Diane Dzierba
Susheel Jethanand Nara
Maheswaran Sivasamban Karatholuvhu
Original Assignee
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Publication of UY34666A publication Critical patent/UY34666A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Abstract

La presente descripción se refiere en general a compuestos que pueden inhibir la AAK1 (quinasa asoc iada con el adaptador 1), composiciones que comprenden tales compuestos y métodos para inhibir la A AK1
UY0001034666A 2012-03-09 2013-03-08 Inhibidores de quinasa a base de ariléter UY34666A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261608737P 2012-03-09 2012-03-09

Publications (1)

Publication Number Publication Date
UY34666A true UY34666A (es) 2013-09-30

Family

ID=47892007

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034666A UY34666A (es) 2012-03-09 2013-03-08 Inhibidores de quinasa a base de ariléter

Country Status (11)

Country Link
US (2) US8703953B2 (es)
EP (1) EP2822952B1 (es)
JP (1) JP2015510881A (es)
CN (1) CN104144932A (es)
AR (1) AR090293A1 (es)
CA (1) CA2866671A1 (es)
EA (1) EA201491647A1 (es)
MX (1) MX2014010684A (es)
TW (1) TW201341387A (es)
UY (1) UY34666A (es)
WO (1) WO2013134036A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
WO2014130258A1 (en) 2013-02-22 2014-08-28 Bristol-Myers Squibb Company 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1)
TW201506024A (zh) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物
CN105518005B (zh) 2013-07-02 2018-07-20 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
EP3019475A1 (en) 2013-07-08 2016-05-18 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
CN105683196B (zh) * 2013-09-11 2018-12-21 百时美施贵宝公司 基于芳基醚的激酶抑制剂
US9737542B2 (en) 2013-10-11 2017-08-22 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN106132414A (zh) * 2014-01-29 2016-11-16 百时美施贵宝公司 芳基内酰胺激酶抑制剂
EP3099673B1 (en) * 2014-01-31 2018-09-26 Bristol-Myers Squibb Company Quinoline-based kinase inhibitors
DK3126351T3 (en) * 2014-04-02 2019-01-14 Bristol Myers Squibb Co BIARYLKINASE INHIBITORS
EP3292124B1 (en) 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
MX2017011447A (es) * 2015-05-22 2018-06-18 Dow Agrosciences Llc Recuperacion y / o reuso de un catalizador de paladio despues de una reaccion de acoplamiento suzuki.
ES2767776T3 (es) * 2015-10-01 2020-06-18 Bristol Myers Squibb Co Inhibidores de biaril cinasa
ES2765730T3 (es) * 2015-10-01 2020-06-10 Bristol Myers Squibb Co Inhibidores de biaril cinasa
TWI766176B (zh) * 2016-12-15 2022-06-01 瑞士商赫孚孟拉羅股份公司 製備btk抑制劑之方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950704228A (ko) 1992-12-02 1995-11-17 알렌 제이. 스피겔 선택적 포스포디에스테르가수분해효소 iv형(pde_iv) 저해제로서의 카테콜 디에테르(catecol diethers as selective pde_iv inhibitors)
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
ATE388946T1 (de) 2002-04-05 2008-03-15 Boehringer Ingelheim Pharma Cyanamide als reversible hemmer von cystein proteasen
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2004072018A1 (ja) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited アミン誘導体
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1773780A4 (en) 2004-06-24 2008-01-09 Incyte Corp AMIDO COMPOUNDS AND USES THEREOF AS PHARMACEUTICAL PRODUCTS
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
MX2008012945A (es) 2006-04-07 2009-01-15 Vertex Pharma Moduladores de transportadores de cartucho de union a adenosina-trifosfato celular (atp).
WO2008022155A2 (en) 2006-08-14 2008-02-21 Wyeth Methods of identifying agents for treating neurological disorders
EP2167976A2 (en) * 2007-05-29 2010-03-31 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
US8497271B2 (en) 2009-10-07 2013-07-30 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88

Also Published As

Publication number Publication date
WO2013134036A1 (en) 2013-09-12
TW201341387A (zh) 2013-10-16
US20130237555A1 (en) 2013-09-12
CN104144932A (zh) 2014-11-12
US20140179725A1 (en) 2014-06-26
JP2015510881A (ja) 2015-04-13
CA2866671A1 (en) 2013-09-12
EP2822952B1 (en) 2016-04-06
US8969564B2 (en) 2015-03-03
US8703953B2 (en) 2014-04-22
EP2822952A1 (en) 2015-01-14
AR090293A1 (es) 2014-11-05
MX2014010684A (es) 2014-10-17
EA201491647A1 (ru) 2014-12-30

Similar Documents

Publication Publication Date Title
UY34666A (es) Inhibidores de quinasa a base de ariléter
UY4276Q (es) Controlador para dispositivo electrónico
UY4211Q (es) Pizarra para marcadores
UY34654A (es) Inhibidores de la beta-secretasa
UY4169Q (es) Altoparlante
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY34817A (es) Tienopirimidinas
UY34027A (es) Inhibidores sustituidos de acetil-coa carboxilasa.
UY33930A (es) Inhibidores novedosos de quinasas
UY34818A (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
UY4281Q (es) Juguera
UY4210Q (es) Silla
UY4223Q (es) Banco
BR112015003294A2 (pt) caldeira de armazenamento
UY4153Q (es) Batería
UY4181Q (es) Taza
UY34677A (es) Imidazopiridazinas sustituidas
UY4152Q (es) Batería
UY4237Q (es) Taburete
UY34518A (es) Composiciones que contienen inhibidores de quinasas
UY34033A (es) ?nuevos inhibidores de quinasa?.
TN2011000372A1 (fr) جهاز مراقبة وتحكم في استهلاك المياه
CL2012003246S1 (es) Escritorio electrónico.
UY4256Q (es) ?motocicleta?.
TN2011000162A1 (fr) نظام هندسي ومعماري مبتكر لانشاء البناء عامة ومواكب للتكنولوجيات المتطورة مادته الاساسية الطين والتربة